Abiopharma

🔍 Giuffre Randall Michael (Executive)

Company: DiaMedica Therapeutics Inc. (DMAC)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 6,175 shares of Common Stock at $8.42 per share (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 398,587.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 25,573.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: H | nature_of_ownership: By Spouse | shares_owned_after: 21,070.00

Footnotes:

• F1: Shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees in the aggregate amount of $52,000. The deferred stock units are scheduled to vest in four nearly equal installments on each of March 31, June 30, September 30, and December 31, 2026.
• F2: These voting common shares are held by 424822 Albert Ltd, of which Michael Giuffre has sole voting and dispositive power.